Turning Stigma Wedges into Chronic Care

Ro’s early edge was not telehealth in general, it was picking conditions where the old care path was emotionally expensive as well as medically inconvenient. A patient with ED or herpes already knows they want treatment, they do not need education or browsing. They need a fast intake, no waiting room, no awkward pharmacy pickup, and medication shipped discreetly, which made a digital flow feel better than an office visit, not merely more convenient.

• Roman’s original menu was built around exactly these high intent categories. Ro’s own care flow covered ED, hair loss, cold sores and genital herpes through online intake, clinician review, and home delivery, turning a stigmatized errand into a private checkout and refill loop.
  3 ro 4 ro
• The business model matched the psychology. Ro and Hims made consults effectively free and monetized the prescription, so the patient could move straight from questionnaire to recurring generic medication, often at a lower out of pocket cost than a traditional visit plus pharmacy copay.
  2 sacra 5 hims 6 hims
• That wedge was powerful, but narrow. By 2021, Roman still accounted for about 60% of Ro revenue, showing how much the company initially depended on sexual health. Ro then used acquisitions like Modern Fertility and later obesity care to apply the same privacy and continuity playbook to broader categories.
  3 ro 7 ro

The next phase is turning this stigma first wedge into a chronic care machine. GLP-1 obesity treatment follows the same basic logic, high intent patients, recurring medication, ongoing follow up, and a strong preference for simple remote care. The companies that win from here will be the ones that turn a one time embarrassing purchase into a long running care relationship across multiple conditions.